Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...

The meeting point of the stomach and esophagus, the so-called gastro-esophageal junction, is a region of the human body that ...

Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...

The Business Research Company's Gastroesophageal Junction Adenocarcinoma Therapeutics Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released ...

At the preferred starting point, about 3 cm above the esophagogastric junction, the esophageal wall is usually normal. As a rule, I do not open the entire longitudinal layer first and then the ...

supporting the continued development of HLX22 as a potential treatment for HER2-positive metastatic gastric and gastroesophageal junction (GEJ) cancer. Henlius is conducting a Phase 3 clinical ...

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic esophageal squamous ... met its primary end point, showing a ...

unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (combined positive score [CPS] of 1 or more). According to an announcement ...

Dosing ongoing in Phase 1 clinical trial cohorts evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ ...